Effect of interferon-a treatment on [68Ga-DOTA,Tyr3,Thre8] octreotide uptake in CA20948 tumors: A small-animal PET study

Journal of Nuclear Medicine

Volumn 52, Issue 4, 2011, Pages 580-585

  Hanin, François Xavier ^a   Pauwels, Stanislas ^a   Bol, Anne ^a   Melis, Marleen ^b   Breeman, Wout ^b   De Jong, Marion ^b   Jamar, François ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

68Ga; Interferon a; Neuroendocrine tumors; Rats; Small animal PE.T.

Indexed keywords

ALPHA INTERFERON; OCTREOTIDE[3 TYROSINE 8 THREONINE] 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID GA 68; RADIOPHARMACEUTICAL AGENT; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG; 68GA DOTATATE; 68GA-DOTATATE; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; ORGANOMETALLIC COMPOUND;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG UPTAKE; MALE; NEUROENDOCRINE TUMOR; NONHUMAN; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR UPREGULATION; TUMOR VOLUME; ANIMAL; CANCER TRANSPLANTATION; EXPERIMENTAL NEOPLASM; IMAGE PROCESSING; LEWIS RAT; METABOLISM; METHODOLOGY; NONLINEAR SYSTEM; SCINTISCANNING; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; IMAGE PROCESSING, COMPUTER-ASSISTED; INTERFERON-ALPHA; MALE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; NONLINEAR DYNAMICS; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, INBRED LEW; TISSUE DISTRIBUTION;

EID: 79954598448     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.084152     Document Type: Article

References (41)

1. Plöckinger U, Rindi G, Arnold R, et al. Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours: A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology. 2004;80:394-424. (Pubitemid 40874886)
2. Ramage J, Davies A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut. 2005;54 (suppl 4):iv1-iv16. (Pubitemid 40695259)
3. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124-2130.
4. Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogues. Nephrol Dial Transplant. 2004;19:2275-2281. (Pubitemid 39214121)
5. Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med. 1983;309:129-133. (Pubitemid 13069520)
6. Plöckinger U, Wiedenmann B. Neuroendocrine tumors: Biotherapy. Best Pract Res Clin Endocrinol Metab. 2007;21:145-162.
7. Fazio N, de Braud F, Delle Fave G, Oberg K. Interferon-a and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: Single agent or combination? Ann Oncol. 2007;18:13-19. (Pubitemid 46152493)
8. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem. 2000;7:971-994.
9. Stolz B, Weckbecker G, Smith-Jones PM, Albert R, Raulf F, Bruns C. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med. 1998;25:668-674. (Pubitemid 28377028)
10. de Jong M, Breeman WA, Bakker WH, et al. Comparison of 111In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy. Cancer Res. 1998;58:437-441. (Pubitemid 28087403)
11. Capello A, Krenning E, Bernard B, Reubi JC, Breeman W, de Jong M. 111Inlabelled somatostatin analogues in a rat tumour model: Somatostatin receptor status and effects of peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging. 2005;32:1288-1295. (Pubitemid 41598720)
12. Guide for the Care and Use of Laboratory Animals. Washington, DC: Government Printing Office; 1985. NIH publication 86[hyphen]23.
13. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP. Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging. 2005;32:478-485.
14. Grander D, Oberg K, Lundqvist ML, Janson ET, Eriksson B, Einhorn S. Interferon- induced enhancement of 29,59-oligoadenylate synthetase in mid-gut carcinoid tumours. Lancet. 1990;336:337-340. (Pubitemid 20264148)
15. Kumaran J, Wei L, Kotra LP, Fish EN. A structural basis for interferon-areceptor interactions. FASEB J. 2007;21:3288-3296.
16. Plath T, Höcker M, Riecken EO, Wang TC, Wiedenmann B, Rosewicz S. Interferon- a inhibits chromogranin A promoter activity in neuroendocrine pancreatic cancer cells. FEBS Lett. 1999;458:378-382. (Pubitemid 29433839)
17. Zhou Y, Wang S, Gobl A, Oberg K. The interferon-a regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors. Ann Oncol. 2000;11:707-714.
18. Brosjö O, Bauer HC, Broström LA, Nilsson OS, Reinholt FP, Tribukait B. Growth inhibition of human osteosarcomas in nude mice by human interferon-a: Significance of dose and tumor differentiation. Cancer Res. 1987;47:258-262.
19. Rosewicz S, Detjen K, Scholz A, von Marschall Z. Interferon-a: Regulatory effects on cell cycle and angiogenesis. Neuroendocrinology. 2004;80(suppl 1):85-93. (Pubitemid 39382376)
20. von Marschall Z, Scholz A, Cramer T, et al. Effects of interferon a on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst. 2003;95:437-448. (Pubitemid 36432418)
21. Zitzmann K, Brand S, De Toni EN, et al. SOCS1 silencing enhances antitumor activity of type I IFNs by regulating apoptosis in neuroendocrine tumor cells. Cancer Res. 2007;67:5025-5032. (Pubitemid 46910213)
22. Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfamediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000;118:735-748. (Pubitemid 30171623)
23. Oberg K. Interferon in the management of neuroendocrine GEP-tumors: A review. Digestion. 2000;62(suppl 1):92-97. (Pubitemid 30665946)
24. Wu S, Murrell GA, Wang Y. Interferon-a (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol Immunother.2002;51:248-254. (Pubitemid 34810705)
25. Scambia G, Panici PB, Ferrandina G, et al. Effect of recombinant human interferon- a/2b on epidermal-growth-factor-, estrogen- and progesterone- receptor expression in primary cervical cancer. Int J Cancer. 1994;58:769-773. (Pubitemid 24306361)
26. Hofland LJ, de Herder WW, Waaijers M, et al. Interferon-a-2a is a potent inhibitor of hormone secretion by cultured human pituitary adenomas. J Clin Endocrinol Metab. 1999;84:3336-3343. (Pubitemid 30646965)
27. Faiss S, Pape UF, Bohmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors: The International Lanreotide and Interferon Alfa Study Group. J Clin Oncol. 2003;21:2689-2696. (Pubitemid 46606312)
28. Shah T, Caplin M. Endocrine tumours of the gastrointestinal tract: Biotherapy for metastatic endocrine tumours. Best Pract Res Clin Gastroenterol. 2005;19:617-636.
29. Fjällskog ML, Sundin A,Westlin JE, Oberg K, Janson ET, Eriksson B. Treatment of malignant endocrine pancreatic tumors with a combination of a-interferon and somatostatin analogs. Med Oncol. 2002;19:35-42. (Pubitemid 34587755)
30. Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): Subtype selective internalization or upregulation. Endocrinology. 1996;137:4046-4049. (Pubitemid 26284682)
31. Froidevaux S, Hintermann E, Török M, Mäcke HR, Beglinger C, Eberle AN. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4- 2J tumor cells implanted into mice during octreotide treatment. Cancer Res.1999;59:3652-3657. (Pubitemid 29381868)
32. Hanin FX, Pauwels S, Bol A, Breeman W, de Jong M, Jamar F. Tumor uptake of 68Ga-DOTA-Tyr3-octreotate: Animal PET studies of tumor flow and acute somatostatin receptor modulation in the CA20948 rat model. Nucl Med Biol. 2010; 37:157-165.
33. Melis M, Forrer F, Capello A, et al. Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3] octreotate therapy. Q J Nucl Med Mol Imaging. 2007;51:324-333. (Pubitemid 350267703)
34. Ben Reguiga M, Bonhomme-Faivre L, Farinotti R. Bioavailability and tissular distribution of docetaxel, a P-glycoprotein substrate, are modified by interferona in rats. J Pharm Pharmacol. 2007;59:401-408. (Pubitemid 47050905)
35. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer. 1998;77:1-10.
36. Pammer J, Reinisch C, Birner P, Pogoda K, Sturzl M, Tschachler E. Interferon-a prevents apoptosis of endothelial cells after short-term exposure but induces replicative senescence after continuous stimulation. Lab Invest. 2006;86:997-1007. (Pubitemid 44423065)
37. Persano L, Moserle L, Esposito G, et al. Interferon-a counteracts the angiogenic switch and reduces tumor cell proliferation in a spontaneous model of prostatic cancer. Carcinogenesis. 2009;30:851-860.
38. Zhu Y, Tibensky I, Schmidt J, et al. Interferon-a in combination with chemotherapy has potent antiangiogenic properties in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother. 2008;31:28-33. (Pubitemid 351619401)
39. Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: A random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol. 2008; 26:1316-1323.
40. Li J, Merton DA, Duggaraju R, Thakur ML. Augmenting of tumor uptake of anti-melanoma antibody MEM136: Influence of interferon. Nucl Med Biol.1996;23:873-879. (Pubitemid 26392229)
41. Li J, Merton DA, Thakur ML, et al. Influence of biological response modifiers: Measurement of tumor blood flow and temperature. J Immunother Emphasis Tumor Immunol. 1994;16:175-180. (Pubitemid 24321449)